MX2010005356A - Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos. - Google Patents

Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.

Info

Publication number
MX2010005356A
MX2010005356A MX2010005356A MX2010005356A MX2010005356A MX 2010005356 A MX2010005356 A MX 2010005356A MX 2010005356 A MX2010005356 A MX 2010005356A MX 2010005356 A MX2010005356 A MX 2010005356A MX 2010005356 A MX2010005356 A MX 2010005356A
Authority
MX
Mexico
Prior art keywords
substituted indole
heterocyclic substituted
methods
indole derivatives
heterocyclic
Prior art date
Application number
MX2010005356A
Other languages
English (en)
Inventor
Brian A Mckittrick
Tin-Yau Chan
Haiyan Pu
Li Wang
Liwu Hong
Charles A Lesburg
Jose S Duca
Henry M Vaccaro
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010005356A publication Critical patent/MX2010005356A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

La presente invención se refiere a derivados de indol 3- heterocíclico sustituidos, composiciones que comprenden por lo menos un derivado de indol 3-heterocíclico sustituido, y métodos de uso de los derivados de indol 3-heterocíclico sustituidos para tratar o prevenir una infección viral o un trastorno relacionado con virus en un paciente.
MX2010005356A 2007-11-16 2008-11-13 Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos. MX2010005356A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98852807P 2007-11-16 2007-11-16
PCT/US2008/083351 WO2009064848A1 (en) 2007-11-16 2008-11-13 3-heterocyclic substituted indole derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2010005356A true MX2010005356A (es) 2010-05-27

Family

ID=40344906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005356A MX2010005356A (es) 2007-11-16 2008-11-13 Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.

Country Status (7)

Country Link
US (1) US8765757B2 (es)
EP (1) EP2222660B1 (es)
JP (1) JP5249344B2 (es)
CN (1) CN102099351A (es)
CA (1) CA2705586A1 (es)
MX (1) MX2010005356A (es)
WO (1) WO2009064848A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
WO2008136815A2 (en) 2006-12-22 2008-11-13 Schering Corporation 5, 6-ring annulated indole derivatives and use thereof
AU2007339386B8 (en) 2006-12-22 2013-12-05 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
CN101631773A (zh) 2006-12-22 2010-01-20 先灵公司 治疗或预防hcv和相关病毒感染的4,5-环化吲哚衍生物
CN101821252A (zh) * 2007-08-29 2010-09-01 先灵公司 取代的吲哚衍生物及其使用方法
TW200911807A (en) * 2007-08-29 2009-03-16 Schering Corp 2,3-substituted azaindole derivatives and methods of use thereof
JP5249344B2 (ja) 2007-11-16 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション ヘテロ環の３位が置換されたインドール誘導体およびその使用
CA2705587A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
EP2303893B1 (en) * 2008-06-13 2016-12-07 Merck Sharp & Dohme Corp. Tricyclic indole derivatives
CN102099335A (zh) 2008-07-23 2011-06-15 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
JP2012503620A (ja) 2008-09-26 2012-02-09 エフ．ホフマン−ラ ロシュ アーゲー Ｈｃｖを処置するためのピリンまたはピラジン誘導体
SG175774A1 (en) 2009-04-25 2011-12-29 Hoffmann La Roche Heterocyclic antiviral compounds
AR077004A1 (es) 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
TW201103545A (en) 2009-06-24 2011-02-01 Hoffmann La Roche Heterocyclic antiviral compound
AU2010297290A1 (en) 2009-09-21 2012-03-15 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2012040124A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
CN113121450A (zh) 2014-08-29 2021-07-16 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
PL3203840T3 (pl) * 2014-10-06 2021-01-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
WO2016161268A1 (en) * 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
EP3313836B1 (en) 2015-06-26 2020-11-11 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10548899B2 (en) 2015-10-20 2020-02-04 Takeda Pharmaceutical Company Limited Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
US10280175B2 (en) 2016-02-02 2019-05-07 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
JP6904970B2 (ja) 2016-03-07 2021-07-21 エナンタ ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎抗ウイルス剤
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN109843296A (zh) 2016-06-10 2019-06-04 英安塔制药有限公司 乙型肝炎抗病毒药剂
WO2018064632A1 (en) 2016-09-30 2018-04-05 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2018107100A1 (en) 2016-12-09 2018-06-14 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019028228A1 (en) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated PROCESSES FOR THE PREPARATION OF PYRROLIDINE COMPOUNDS
MX2020002191A (es) 2017-08-28 2020-10-05 Enanta Pharm Inc Agentes antivirales contra la hepatitis b.
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
US10428070B2 (en) 2017-12-06 2019-10-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10723733B2 (en) 2017-12-06 2020-07-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
AU2018380426B2 (en) 2017-12-08 2023-05-18 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019191166A1 (en) 2018-03-29 2019-10-03 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
US10865211B2 (en) 2018-09-21 2020-12-15 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
JP2022507724A (ja) 2018-11-21 2022-01-18 エナンタ ファーマシューティカルズ インコーポレイテッド 抗ウイルス剤としての官能化複素環
CN112028815A (zh) * 2019-06-03 2020-12-04 中国药科大学 吲哚类衍生物及其医药用途
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE648639C (de) 1935-05-19 1937-08-05 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Dipyrrolen
US3632805A (en) 1967-12-08 1972-01-04 Sumitomo Chemical Co Process for producing 1-aminoalkyl-benzodiazepine derivatives
AU575854B2 (en) 1983-10-04 1988-08-11 Shionogi & Co., Ltd. 7beta-(carboxyalkenamido) cephalosporins
NZ220764A (en) 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
US5017380A (en) 1986-07-02 1991-05-21 Shionogi & Co., Ltd. Gelatin hard capsule containing crystalline hydrate of oral cephalosporin
CA2038925A1 (en) 1990-03-26 1991-09-27 Takashi Sohda Indole derivatives, their production and use
JPH04149429A (ja) 1990-10-12 1992-05-22 Fuji Photo Film Co Ltd ハロゲン化銀カラー反転写真感光材料およびそれを用いた画像形成方法
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
BR9712544B1 (pt) 1996-10-18 2013-10-22 Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
FR2768146B1 (fr) 1997-09-05 2000-05-05 Oreal Nouveaux composes de la famille des indole-carboxyliques et leur utilisation
EP1268525B1 (en) 2000-04-05 2008-12-31 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
AR030558A1 (es) 2000-04-19 2003-08-27 Schering Corp COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA,
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
RU2003105221A (ru) 2000-07-21 2004-09-20 Шеринг Корпорейшн (US) Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с
AU2001276988B2 (en) 2000-07-21 2007-01-25 Dendreon Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
KR20030036917A (ko) 2000-10-10 2003-05-09 스미스클라인 비참 코포레이션 치환된 인돌, 이를 함유하는 약제학적 조성물, 및 이의ＰＰＡＲ-γ결합제로서의 용도
WO2002048172A2 (en) 2000-12-12 2002-06-20 Schering Corporation Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
CA2430808A1 (en) 2000-12-18 2002-06-27 Eli Lilly And Company Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
WO2002068412A1 (en) 2001-02-22 2002-09-06 School Of Pharmacy, University Of London Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
JP2006505571A (ja) 2002-10-15 2006-02-16 リゲル ファーマシューテイカルズ、インコーポレイテッド 置換されたインドール及びｈｃｖ阻害剤としてのその使用
US20050075331A1 (en) 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
GB0307891D0 (en) * 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
NZ543897A (en) 2003-05-30 2009-04-30 Gemin X Pharmaceuticals Canada Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
GB0323845D0 (en) 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
PE20090047A1 (es) 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
NZ549223A (en) 2004-02-27 2010-10-29 Schering Corp Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
MXPA06009881A (es) 2004-03-01 2007-11-20 Viropharma Inc Derivados de piranoindol y el uso de los mismos para el tratamiento de infeccion o enfermedad de virus de hepatitis c.
AR049635A1 (es) 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
WO2006034337A2 (en) 2004-09-23 2006-03-30 Wyeth Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus
DE102004047272A1 (de) 2004-09-24 2006-04-06 Schering Ag Inhibitoren der löslichen Adenylatzyklase
JP4149429B2 (ja) 2004-10-26 2008-09-10 本田技研工業株式会社 車両の走行安全装置
JP2008517987A (ja) 2004-10-26 2008-05-29 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス薬としての四環式インドール誘導体
WO2006076529A1 (en) 2005-01-14 2006-07-20 Genelabs Technologies, Inc. Indole derivatives for treating viral infections
US20110104109A1 (en) 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7482360B2 (en) 2005-09-23 2009-01-27 Schering Corporation Fused tetracyclic mGluR1 antagonists as therapeutic agents
WO2007084435A2 (en) 2006-01-13 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
PE20080197A1 (es) 2006-02-09 2008-04-11 Schering Corp Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s)
AU2007339386B8 (en) 2006-12-22 2013-12-05 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
WO2008136815A2 (en) 2006-12-22 2008-11-13 Schering Corporation 5, 6-ring annulated indole derivatives and use thereof
CN101631773A (zh) 2006-12-22 2010-01-20 先灵公司 治疗或预防hcv和相关病毒感染的4,5-环化吲哚衍生物
US20090047246A1 (en) * 2007-02-12 2009-02-19 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
TW200911807A (en) 2007-08-29 2009-03-16 Schering Corp 2,3-substituted azaindole derivatives and methods of use thereof
BRPI0816116A2 (pt) * 2007-08-29 2015-03-03 Schering Corp Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
CN101821252A (zh) * 2007-08-29 2010-09-01 先灵公司 取代的吲哚衍生物及其使用方法
SG183733A1 (en) * 2007-09-17 2012-09-27 Abbott Lab Uracil or thymine derivative for treating hepatitis c
JP5249344B2 (ja) 2007-11-16 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション ヘテロ環の３位が置換されたインドール誘導体およびその使用
CA2705587A1 (en) 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof

Also Published As

Publication number Publication date
JP2011503195A (ja) 2011-01-27
CA2705586A1 (en) 2009-05-22
JP5249344B2 (ja) 2013-07-31
US8765757B2 (en) 2014-07-01
WO2009064848A1 (en) 2009-05-22
US20110165118A1 (en) 2011-07-07
CN102099351A (zh) 2011-06-15
EP2222660B1 (en) 2014-03-26
EP2222660A1 (en) 2010-09-01

Similar Documents

Publication Publication Date Title
MX2010005356A (es) Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
MX2010002317A (es) Derivados de indol sustituidos y metodos para su utilizacion.
MX2010005355A (es) Derivados de indol sustituidos con 3-aminosulfonilo y metodos de uso de los mismos.
MX2010002316A (es) Derivados tetraciclicos de indol y su uso para el tratamiento o prevencion de infecciones virales.
MX2010002319A (es) Derivados indolicos 2,3 sustituidos para el tratamiento de infecciones virales.
TW200833662A (en) 4,5-ring annulated indole derivatives and methods of use thereof
TW200833684A (en) 5,6-ring annulated indole derivatives and methods of use thereof
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
IL248522B (en) Compositions of Live Attenuated Viruses, and Methods of Inactivating Live Attenuated Virus Compositions
CL2012001176A1 (es) Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
WO2008127364A3 (en) Antiviral compounds and use thereof
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
IL209380A0 (en) Small molecule inhibitors for the treatment or prevention of dengue virus infection
MX2012000959A (es) Inhibidores de los virus flaviviridae.
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
UA100250C2 (uk) Інгібітори реплікації вірусу імунодефіциту людини
WO2008115281A3 (en) Compounds for treating viral infections
MX2009013828A (es) Composiciones terapeuticas y su uso.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
GB2466912A (en) Compositions and methods for treating lysosomal disorders
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren

Legal Events

Date Code Title Description
FA Abandonment or withdrawal